Signatures of miR-181a on the renal transcriptome and blood pressure

Molecular Medicine

Volumn 21, Issue , 2015, Pages 739-748

  Marques, Francine Z ^a   Romaine, Simon P R ^b   Denniff, Matthew ^b   Eales, James ^b   Dormer, John ^c   Garrelds, Ingrid M ^d   Wojnar, Lukasz ^e   Musialik, Katarzyna ^e   Duda Raszewska, Barbara ^f   Kiszka, Bartlomiej ^f   Duda, Magdalena ^f   Morris, Brian J ^g   Samani, Nilesh J ^b,h   Jan Danser, A H ^d   Bogdanski, Pawel ^e   Zukowska Szczechowska, Ewa ^f   Charchar, Fadi J ^a   Tomaszewski, Maciej ^b,i  

^a UNIVERSITY OF BALLARAT   (Australia)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g UNIVERSITY OF SYDNEY   (Australia)

^h GLENFIELD HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 181A; RENIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; KIDNEY; KIDNEY COLLECTING TUBULE; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; MOLECULAR INTERACTION; NEXT GENERATION SEQUENCING; PLASMA RENIN ACTIVITY; PLEIOTROPY; PRIORITY JOURNAL; RNA ANALYSIS; RNA SEQUENCE; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TRANSCRIPTOMICS;

EID: 84975109801     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2015.00096     Document Type: Article

References (57)

1. Rapsomaniki E, et al. (2014) Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 383:1899-911.
2. Charchar F, Zimmerli L, Tomaszewski M. (2008) The pressure of finding human hypertension genes: new tools, old dilemmas. J. Hum. Hypertens. 22:821-8.
3. Iaconetti C, Gareri C, Polimeni A, Indolfi C. (2013) Non-coding RNAs: the “dark matter” of cardiovascular pathophysiology. Int. J. Mol. Sci. 14:19987-20018.
4. Marques FZ, Booth SA, Charchar FJ. (2015) The emerging role of non-coding RNA in essential hypertension and blood pressure regulation. J. Hum. Hypertens. 29:459-67.
5. Romaine SP, Tomaszewski M, Condorelli G, Samani NJ. (2015) MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart. 101:921-8.
6. Hamid SM, Akgul B. (2014) Master regulators of posttranscriptional gene expression are subject to regulation. Methods Mol Biol. 1107:303-10.
7. Pasquinelli AE. (2012) MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat. Rev. Genet. 13:271-82.
8. Creemers EE, Tijsen AJ, Pinto YM. (2012) Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ. Res. 110:483-95.
9. Marques FZ, et al. (2011) Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension. 58:1093-8.
10. Jackson KL, et al. (2013) A novel interaction between sympathetic overactivity and aberrant regulation of renin by miR-181a in BPH/2J genetically hypertensive mice. Hypertension. 62:775-81.
11. Tomaszewski M, et al. (2011) Pathway analysis shows association between FGFBP1 and hypertension. J. Am. Soc. Nephrol. 22:947-55.
12. Tomaszewski M, et al. (2007) Fibroblast growth factor 1 gene and hypertension: from the quantitative trait locus to positional analysis. Circulation. 116:1915-24.
13. Tomaszewski M, et al. (2015) Renal mechanisms of association between fibroblast growth factor 1 and blood pressure. J. Am. Soc. Nephrol. 26:3151-60.
14. Tomaszewski M, et al. (2010) Genetic architecture of ambulatory blood pressure in the general population: insights from cardiovascular gene-centric array. Hypertension. 56:1069-76.
15. Ehret GB, Caulfield MJ. (2013) Genes for blood pressure: an opportunity to understand hypertension. Eur. Heart J. 34:951-61.
16. Smyth GK. (c2005) limma: Linear Models for Microarray Data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S (eds.) Springer, New York, pp. 397-420.
17. Subramanian A, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102:15545-50.
18. GTEx Consortium. (2013) The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45:580-5.
19. Abd-Allah NM, Hassan FH, Esmat AY, Hammad SA. (2004) Age dependence of the levels of plasma norepinephrine, aldosterone, renin activity and urinary vanillylmandelic acid in normal and essential hypertensives. Biol. Res. 37:95-106.
20. Uckaya G, et al. (1999) Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm. Metab. Res. 31:435-8.
21. Vetter H, Glanzer K, Vetter W. (1980) Essential hypertension: relationship between renin and blood pressure. Clin. Exp. Hypertens. 2:553-61.
22. Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H. (1998) Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J. Hypertens. 16:853-62.
23. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. (1999) The renin-angiotensin system and blood pressure: differences between blacks and whites. Am. J. Hypertens. 12:555-62.
24. Lucas CP, et al. (1974) Disturbed relationship of plasma-renin to blood-pressure in hypertension. Lancet. 2:1337-9.
25. Williams B, Baschiera F, Lacy PS, Botha J, Prescott MF, Brunel P. (2013) Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise. J. Renin Angiotensin Aldosterone Syst. 14:56-66.
26. He FJ, Markandu ND, MacGregor GA. (2001) Importance of the renin system for determining blood pressure fall with acute salt restriction in hypertensive and normotensive whites. Hypertension. 38:321-5.
27. Medrano S, Monteagudo MC, Sequeira-Lopez ML, Pentz ES, Gomez RA. (2012) Two microRNAs, miR-330 and miR-125b-5p, mark the juxtaglomerular cell and balance its smooth muscle phenotype. Am. J. Physiol. Renal Physiol. 302:F29-37.
28. Hu Y, Li P, Hao S, Liu L, Zhao J, Hou Y. (2009) Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin. Chem. Lab Med. 47:923-9.
29. Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. (2011) Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod. Sci. 18:46-56.
30. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. (2011) Intratubular renin-angiotensin system in hypertension. Hypertension. 57:355-62.
31. Prieto-Carrasquero MC, Botros FT, Kobori H, Navar LG. (2009) Collecting duct renin: A major player in angiotensin II-dependent hypertension. J. Am. Soc. Hypertens. 3:96-104.
32. Ramkumar N, Stuart D, Rees S, Hoek AV, Sigmund CD, Kohan DE. (2014) Collecting duct-specific knockout of renin attenuates angiotensin II-induced hypertension. Am. J. Physiol. Renal Physiol. 307:F931-8.
33. Ramkumar N, Ying J, Stuart D, Kohan DE. (2013) Overexpression of renin in the collecting duct causes elevated blood pressure. Am J. Hypertens. 26:965-72.
34. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. (2008) The impact of microRNAs on protein output. Nature. 455:64-71.
35. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature. 455:58-63.
36. Li QJ, et al. (2007) miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 129:147-61.
37. Liu L, et al. (2012) MicroRNA-181a regulates local immune balance by inhibiting proliferation and immunosuppressive properties of mesenchymal stem cells. Stem Cells. 30:1756-70.
38. Kroesen BJ, et al. (2015) Immuno-miRs: critical regulators of T-cell development, function and ageing. Immunology. 144:1-10.
39. Xie W, et al. (2013) miR-181a regulates inflammation responses in monocytes and macrophages. PLoS One. 8:e58639.
40. Xie W, Li Z, Li M, Xu N, Zhang Y. (2013) miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo. Biochem. Biophys. Res. Commun. 430:647-52.
41. Rippo MR, Olivieri F, Monsurro V, Prattichizzo F, Albertini MC, Procopio AD. (2014) MitomiRs in human inflamm-aging: A hypothesis involving miR-181a, miR-34a and miR-146a. Exp. Gerontol. 56C:154-63.
42. Ouyang YB, Lu Y, Yue S, Giffard RG. (2012) miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion. 12:213-9.
43. Harrison DG, Vinh A, Lob H, Madhur MS. (2010) Role of the adaptive immune system in hypertension. Curr. Opin. Pharmacol. 10:203-7.
44. Lob HE, et al. (2010) Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension. 55:277-83.
45. Schiffrin EL. (2010) T lymphocytes: a role in hypertension? Curr. Opin. Nephrol. Hypertens. 19:181-6.
46. Chan SH, Wu KL, Chang AY, Tai MH, Chan JY. (2009) Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. Hypertension. 53:217-27.
47. de Cavanagh EM, Toblli JE, Ferder L, Piotrkowski B, Stella I, Inserra F. (2006) Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290:R1616-25.
48. Eirin A, Lerman A, Lerman LO. (2014) Mitochondrial injury and dysfunction in hypertension-induced cardiac damage. Eur. Heart J. 35:3258-66.
49. Jin K, Vaziri ND. (2014) Salt-sensitive hypertension in mitochondrial superoxide dismutase deficiency is associated with intra-renal oxidative stress and inflammation. Clin. Exp. Nephrol. 18:445-52.
50. Harrison DG, et al. (2011) Inflammation, immunity, and hypertension. Hypertension. 57:132-40.
51. Schiffrin EL. (2014) Immune mechanisms in hypertension and vascular injury. Clin. Sci. (Lond). 126:267-74.
52. Rodriguez-Iturbe B, Pons H, Quiroz Y, Lanaspa MA, Johnson RJ. (2014) Autoimmunity in the pathogenesis of hypertension. Nat. Rev. Nephrol. 10:56-62.
53. Stewart T, Jung FF, Manning J, Vehaskari VM. (2005) Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney Int. 68:2180-8.
54. Schena FP, Serino G, Sallustio F. (2014) MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring. Nephrol. Dial. Transplant. 29:755-63.
55. Kaudewitz D, et al. (2013) Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb. Haemost. 110:609-15.
56. Willeit P, et al. (2013) Circulating microRNAs as novel biomarkers for platelet activation. Circ. Res. 112:595-600.
57. Rodwell GEJ, et al. (2004) A transcriptional profile of aging in the kidney. PLoS Biol. 2:e427.